AXA Partners Signs With Upptec to Automate the Claims Process
AXA Partners Germany and the Swedish-based Insurtech company Upptec will partner up for AXA Partners claims automation roll-out. The partnership will be the first of its kind in Germany and the data-driven claims valuation will center around all household electronics for its initial implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005815/en/
AXA Partners Signs With Upptec to Automate the Claims Process (Graphic: Business Wire)
Upptec has implemented claims automation within home contents in most parts of Europe, but this will be the first customer in Germany to roll-out data-driven and automated claims valuation for electronics based on real time local data with full automation capabilities.
“We as AXA Partners are delighted to announce the integration of Upptec’s valuation solution into our claims process. This will allow us to quickly support our customers in replacing their most valued possessions directly to their home and bring the customer experience to the next level. We look forward to working with Upptec to optimize and automate claims handling in the German market for the benefit of the policyholder.” — explains Kirsten Wenz, TPA Manager Consumer Electronics, AXA Partners Germany.
“We are extremely proud to be delivering a claims valuation solution with real-time responses from the local market for AXA Partners. This is the start of a partnership with great potential, and we see many common objectives by digitizing and automating the claims process, - making it transparent, objective and fast for the German policyholders that will set new standards for digital claims in Germany.” – says Magnus Franck, CEO at Upptec.
About AXA Partners Germany
AXA Partners is part of the international AXA Group, headquartered in Paris, and is one of the world's leading assistance and insurance providers worldwide. With more than 1000 business partners all over the world AXA Partners is working on innovative solutions for more security and a better quality of life. Worldwide, AXA Partners has more than 9000 employees. With this strong network and service partners in more than 200 countries, AXA Partners provides its customers with reliable support in the event of a claim — around the globe, 24 hours a day, 365 days a year.
For more information visit: www.axapartners.de
About Upptec
Upptec wants to transform the world’s insurance industry by making digital claims simple, fast, and effortless. From the first notice of loss to settlement, we automate the claims processes. Since the start Upptec have reduced costs, increased efficiencies, and driven circularity in a sustainable way-of-thinking for partners and customers while at the same time providing the best digital consumer centric experience.
For more information visit: https://upptec.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005815/en/
Contact information
Press Contact - Upptec
Matilda Hansson
Upptec AB
pr@upptec.com
Press Contact – AXA Partners
Roxana Müller
AXA Partners | AXA Assistance Deutschland GmbH
presse@axa-assistance.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom